Information About 4 Stocks (AFFY, NVAX, CG, VRA)

New York City, NY -- (SBWIRE) -- 06/06/2013 -- Affymax, Inc. (NASDAQ:AFFY) short interest increased last 30 days from 42% to 49% as the truth set in of the organization's non-reflex remember of its only FDA-approved medication, Omontys, in Feb. Omontys, a medication used to cure anemia, triggered serious negative activities in 0.2% of sufferers, such as anaphylaxis.It's quite possible that Omontys may never create it returning to promote, and that's quite terrifying, as it currently makes up Affymax's whole direction (Affymax had two extra scientific tests continuous that used Omontys as the mixture therapy).if Omontys controls to create it returning to promote, it could be with a unpleasant caution brand that cripples its sales prospective.